Sutro Biopharma Inc (STRO) Received its Third Buy in a Row

By Ryan Adsit

After Piper Jaffray and JMP Securities gave Sutro Biopharma Inc (NASDAQ: STRO) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Boris Peaker maintained a Buy rating on Sutro Biopharma Inc today. The company’s shares opened today at $12.65.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.3% and a 41.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

Sutro Biopharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $23.67.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.90 and a one-year low of $10.83. Currently, Sutro Biopharma Inc has an average volume of 132.8K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STRO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sutro Biopharma Inc. engages in the drug discovery, development, and manufacturing of pharmaceutical products. Its products technologies include XpressCF; anti-body drug conjugates; bispecifics and engineered antibodies; and cGMP facility. The company was founded in June 2003 and is headquartered in South San Francisco, CA.